Abril-Junio 2004 N°19
ISSN 1317-987X
 
Buscar




Artículos
 
Introducción
Inmunopatología de la infección VIH
La triterapia
Beneficios clínicos
Problemas relacionados con la triterapia
Posibles alternativas
Conclusiones
Referencias




Inmunología
Beneficios y ventajas de la terapia antiretroviral altamente activa (HAART). Otras alternativas

Referencias

  1. Alfonzo M, Blanc D, Troadec C, Eliaszewicz M, Gonzalez G, Scott-Algara D.(2003) Partial restoration of cytokine profile despite reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients during highly active antiretroviral treatment. Scand J Immunol. Apr;57(4):375-83.
  2. Altfeld, M., and Rosenberg, E. S. (2000). The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 12(4), 375-80
  3. Andersson, J., T. E. Fehniger, B. K. Patterson, J. Pottage, M. Agnoli, P. Jones, H. Behbahani, and A. Landay (1998). Early reduction of immune activation in lymphoid tissue following highly active HIV therapy Aids. 12:F123-9.
  4. Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debre, P., and Leibowitch, J. (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277(5322), 112-6.
  5. Badley, A. D., Pilon, A. A., Landay, A., and Lynch, D. H. (2000). Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96(9), 2951-64.
  6. Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux , C.; Rozenbaum, W.; Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for adquired immune deficiency syndrome (AIDS). Science. 220 : 868-871
  7. Berger, E.A.; Murphy, P.M.; Farber, J.M. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 17:657-700.
  8. Bleul, C.C.; Fuhlbrigge, R.C.; Casasnovas, J.M.; Aiuti, A.and Springer, T.A. (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 84(3): 1101-9
  9. Bonhoeffer, S.;Rembiszewski, M.; Ortiz, G. M. and Nixon, D. F. (2000). Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. Aids 14(15), 2313-22.
  10. Bucy, R. P., R. D. Hockett, C. A. Derdeyn, M. S. Saag, K. Squires, M. Sillers, R. T. Mitsuyasu, and J. M. Kilby (1999). Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues J Clin Invest. 103:1391-8
  11. Cameron, P. U., Freudenthal, P. S., Barker, J. M., Gezelter, S., Inaba, K., and Steiman, R. M. (1992). Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 257(5068), 383-7.
  12. Cameron, P. U., Lowe, M. G., Sotzik, F., Coughlan, A. F., Crowe, S. M., and Shortman, K. (1996). the interaction of macrophage and non-macrophage tropic isolates of hiv- 1 with thymic and tonsillar dendritic cells in vitro. J Exp Med 183(4), 1851-6.
  13. Carcelain, G., C. Blanc, J. Leibowitch, P. Mariot, D. Mathez, V. Schneider, A. G. Saimot, F. Damond, F. Simon, P. Debre, B. Autran, and P. M. Girard (1999). T cell changes after combined nucleoside analogue therapy in HIV primary infection Aids. 13:1077-81.
  14. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding (1998). Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel Jama. 280:78-86.
  15. Clerici, M., Stocks, N. I., Zajac, R. A., Boswell, R. N., Lucey, D. R., Via, C. S., and Shearer, G. M. (1989). Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 84(6), 1892-9.
  16. Coffin, J.; Haase, A.; Levy, J.A.; Montagnier, L.; Oroszlan, S.; Teich, N.; Temin, H.; Toyoshima, K.; Varmus, H.; Vogt P. and Weiss, R. Human immunodeficiency viruses. (1986). Science. 232(4751):697.
  17. Dalgleish, A.G.; Beverley, P.C.; Clapman, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312: 763-767.
  18. Dimitrov DS. (1997). How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell. 91(6):721-30.
  19. Dybul, M., Chun, T. W., Yoder, C., Hidalgo, B., Belson, M., Hertogs, K., Larder, B., Dewar, R. L., Fox, C. H., Hallahan, C. W., Justement, J. S., Migueles, S. A., Metcalf, J. A., Davey, R. T., Daucher, M., Pandya, P., Baseler, M., Ward, D. J., and Fauci, A. S. (2001). Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 98(26), 15161-6
  20. Fauci, A.S. (1996). Host factors and the pathogenesis of HIV-induced disease. Nature. 384(6609):529-534.
  21. Gallo, R.C. ; Sarin, P.S. ; Gelmann, E.P. ; Robert-Guroff, M. ; Richardson, E.; Kalyanaraman, V.S.; Mann, D.; Sidhu, G.D.; Sthal, R.E.; Zoila-Pazner, S.; Leibowitch, J. and Popovic, M. (1983). Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 220: 865-867.
  22. Graziosi, C.; Soudeyns, H.; Rizzardi, G.P.; Bart, P.A.; Chapuis, A.; Pantaleo, G. (1998). Immunopathogenesis of HIV infection. AIDS Res. Hum. Retroviruses. 14:S135-S142.
  23. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N Engl J Med. 337:734-9.
  24. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N Engl J Med. 337:725-33
  25. Hanvelt RA, Ruedy NS, Hogg RS, Strachdee S, Montaner JSG, O'Shaughnessy MV, Schecter MT. (1994). Indirect costs of HIV/AIDS mortality in Canada. AIDS. 8:F7-F11.
  26. Hellerstein, M. K., and McCune, J. M. (1997). T cell turnover in HIV-1 disease. Immunity 7(5), 583-9.
  27. Ho, D.D.; Neumann, A.U.; Perelson, A.S.; Chen, W.; Leonard, J.M.; Markowitz, M.(1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373(6510):123-6
  28. Hogg, R. S., M. V. O'Shaughnessy, N. Gataric, B. Yip, K. Craib, M. T. Schechter, and J. S. Montaner (1997). Decline in deaths from AIDS due to new antiretrovirals Lancet. 349:1294.
  29. International Labour Organization. 2000. HIV/AIDS: a threat to decent work, productivity and development. International Labour Organization, Geneva, Switzerland.
  30. Kaufmann, D., G. Pantaleo, P. Sudre, and A. Telenti (1998). CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study Lancet. 351:723-4.
  31. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat Med. 4:1302-7.
  32. Klatzmann, D.; Barre-Sinoussi, F.; Nugeyre, MT.; Danquet, C.; Vilmer, E.; Griscelli, C.; Brun-Veziret, F.; Rouzioux, C.; Gluckman, J.C. and Chermann, J.C. (1984a). Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 225(4657):59-63.
  33. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman, J.C. and Montagnier, L. (1984b). T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312(5996):767-8.
  34. Komanduri, K. V., Feinberg, J., Hutchins, R. K., Frame, R. D., Schmidt, D. K., Viswanathan, M. N., Lalezari, J. P., and McCune, J. M. (2001). Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 183(8), 1285-9.
  35. Lederman, M. M. 2001. Immune restoration and CD4+ T-cell function with antiretroviral therapies Aids. 15 Suppl 2:S11-5.
  36. Lisziewicz, J., Rosenberg, E., Lieberman, J., Jessen, H., Lopalco, L., Siliciano, R., Walker, B., and Lori, F. (1999). Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 340(21), 1683-4.
  37. Marriott, D. & McMurchie, M. (1996). Managing HIV. Part 2: Phases of disease. 2.4 HIV and advanced immune deficiency. Med. J. Aust. 164(2): 111-2
  38. Miedema, F., Petit, A. J., Terpstra, F. G., Schattenkerk, J. K., de Wolf, F., Al, B. J., Roos, M., Lange, J. M., Danner, S. A., Goudsmit, J., and et al. (1988). Immunological abnormalities in human immunodeficiency virus (HIV)- infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 82(6), 1908-14.
  39. Miller, V., Sabin, C., Hertogs, K., Bloor, S., Martinez-Picado, J., D'Aquila, R., Larder, B., Lutz, T., Gute, P., Weidmann, E., Rabenau, H., Phillips, A., and Staszewski, S. (2000). Virological and immunological effects of treatment interruptions in HIV- 1 infected patients with treatment failure. Aids 14(18), 2857-67.
  40. Neumann, A. U., Tubiana, R., Calvez, V., Robert, C., Li, T. S., Agut, H., Autran, B., and Katlama, C. (1999). HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. Aids 13(6), 677-83.
  41. NIH. Plan del año fiscal 2003 de los NIH para investigaciones relacionadas con el VIH. (2003). 1-40
  42. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J.L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J.M.; Clark-Lewis, I.; Legler, D.F.; Loetscher, M.; Baggiolini, M. and Pantaleo, G.; Fauci, A.S. (1996). Immunopathogenesis of HIV infection. Annu. Rev. Microbiol. 50:825-854.
  43. Ortiz, G. M., Nixon, D. F., Trkola, A., Binley, J., Jin, X., Bonhoeffer, S., Kuebler, P. J., Donahoe, S. M., Demoitie, M. A., Kakimoto, W. M., Ketas, T., Clas, B., Heymann, J. J., Zhang, L., Cao, Y., Hurley, A., Moore, J. P., Ho, D. D., and Markowitz, M. (1999). HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 104(6), R13-8.
  44. Pakker, N. G., D. W. Notermans, R. J. de Boer, M. T. Roos, F. de Wolf, A. Hill, J. M. Leonard, S. A. Danner, F. Miedema, and P. T. Schellekens (1998). Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation Nat Med. 4:208-14.
  45. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med. 338:853-60.
  46. Pantaleo, G., and Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annu Rev Microbiol 50, 825-54.
  47. Pérez-Casas, C.; Verman, D.; Chirac, P.; Kasper, T.; Pécoul, B.; Vicenzi, I., Von Schoen, T. Proyecto de acceso a medicamentos esenciales. Médicos sin fronteras. 2000.
  48. Pérez-Casas, C.; Verman, D.; Chirac, P.; Kasper, T.; Pécoul, B.; Vicenzi, I., Von Schoen, T(2000). Proyecto de acceso a medicamentos esenciales. Médicos sin fronteras.
  49. Plana, M., Garcia, F., Gallart, T., Miro, J. M., and Gatell, J. M. (1998). Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 352(9135), 1194-5.
  50. PNUD. Informe sobre el Desarrollo Humano en el año 2000: Derechos Humanos y Desarrollo Humano. (2000).
  51. Richman, D. D. (2001). HIV Chemotherapy. Nature. 410 (6831): 995-2001.
  52. Rinaldo, C. R., Jr., Liebmann, J. M., Huang, X. L., Fan, Z., Al-Shboul, Q., McMahon, D. K., Day, R. D., Riddler, S. A., and Mellors, J. W. (1999). Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 179(2), 329-36.
  53. Rizzardi, G. P., G. Tambussi, P. A. Bart, A. G. Chapuis, A. Lazzarin, and G. Pantaleo 2000. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count Aids. 14:2257-63.
  54. Rosok, B. I., Bostad, L., Voltersvik, P., Bjerknes, R., Olofsson, J., Asjo, B., and Brinchmann, J. E. (1996). Reduced CD4 cell counts in blood do not reflect CD4 cell depletion in tonsillar tissue in asymptomatic HIV-1 infection. Aids 10(10), F35-8.
  55. Rosenberg, E. S., M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes, R. L. Eldridge, G. K. Robbins, R. T. D'Aquila, P. J. Goulder, and B. D. Walker 2000. Immune control of HIV-1 after early treatment of acute infection Nature. 407:523-6.
  56. Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. A., and Walker, B. D. (1997). Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278(5342), 1447-50.
  57. Sachsenberg, N., A. S. Perelson, S. Yerly, G. A. Schockmel, D. Leduc, B. Hirschel, and L. Perrin 1998. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen J Exp Med. 187:1295-303.
  58. Sam, B. ONUSIDA., citado en OMS-Health and Technology Pharmaceuticals, Estrategia Revisada de Medicamentos, 2001.
  59. Sloand, E. M., P. N. Kumar, S. Kim, A. Chaudhuri, F. F. Weichold, and N. S. Young 1999. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo Blood. 94:1021-7.
  60. Spira, A. I., Marx, P. A., Patterson, B. K., Mahoney, J., Koup, R. A., Wolinsky, S. M., and Ho, D. D. (1996). Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183(1), 215-25.
  61. Staszewski, S., V. Miller, C. Sabin, C. Schlecht, P. Gute, S. Stamm, T. Leder, A. Berger, E. Weidemann, A. Hill, and A. Phillips 1999. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy Aids. 13:951-6
  62. Stein, D.S.; Korvick, J.A.; Vermund, S.H. (1992). CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J. Infect. Dis. 165(2):352-363.
  63. Tenner-Racz, K., H. J. Stellbrink, J. van Lunzen, C. Schneider, J. P. Jacobs, B. Raschdorff, G. Grosschupff, R. M. Steinman, and P. Racz 1998. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy J Exp Med. 187:949-59.
  64. UNAIDS (1999). AIDS epidemic update: December 1999. UNAIDS, Geneva, Switzerland.
  65. UNAIDS. (2000). Report on the global HIV-AIDS epidemic
  66. UNAIDS. (2003). Report on the global HIV-AIDS epidemic
  67. Urbaneja, María. Ponencia ante el 26° período extraordinario de sesiones de la Asamblea General de las Naciones Unidas dedicado a la revisión del VIH/SIDA en todos sus aspectos. (2001). New York, E.E.U.U.
  68. USAID. (1999a). HIV/AIDS briefs: the economic impact of AIDS. USAID, Washington, D.C.
  69. USAID. (1999b). The economic impact of AIDS in Africa. USAID, Washington, D.C.
  70. Youle, M. (2000). Is interruption of HIV therapy always harmful? J Antimicrob Chemother 45(2), 137-8.
  71. Wei, X.; Ghosh, S.K.; Taylor, M.E.; Johnson, V.A.; Emini, E.A.; Deutsch, P.; Lifson, J.D.; Bonhoeffer, S.; Nowak , M.A.; Hahn, B.H. ( 1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373(6510):117-22.
  72. Wolthers, K. C., Schuitemaker, H., and Miedema, F. (1998). Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. Immunol Today 19(1), 44-8.
  73. World Bank. (1993). World development report 1993: investing in health. Oxford Press, New York, N.Y.
  74. World Bank. (1997). Confronting AIDS: public priorites in a global epidemic. World Bank, New York, N.Y.
  75. World Bank. (1993). Investing in HIV/AIDS. World Bank, Washington, D.C.
  76. Vigh, L.; Maresca, B.; Harwood, J. L. (1998) Does the membrane's physical state control the expression of heat shock and other genes? Trends Biochem Sci. 23(10), 369-74
  77. Vigouroux, C.; Gharakhanian, S.; Salhi, Y.; Nguyen, T. H.; Chevenne, D.; Capeau, J. and Rozenbaum, W. (1999). Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 25 (3), 225-232.
  78. Zhang, Z. Q., Notermans, D. W., Sedgewick, G., Cavert, W., Wietgrefe, S., Zupancic, M., Gebhard, K., Henry, K., Boies, L., Chen, Z., Jenkins, M., Mills, R., McDade, H., Goodwin, C., Schuwirth, C. M., Danner, S. A., and Haase, A. T. (1998). Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A 95(3), 1154-9.
Introducción
Inmunopatología de la infección VIH
La triterapia
Beneficios clínicos
Problemas relacionados con la triterapia
Posibles alternativas
Conclusiones
Referencias

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit